Bank of New York Mellon Corp raised its position in shares of Synthetic Biologics Inc (NYSEMKT:SYN) by 3.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,598 shares of the company’s stock after buying an additional 7,962 shares during the period. Bank of New York Mellon Corp’s holdings in Synthetic Biologics were worth $166,000 as of its most recent SEC filing.

Separately, Norges Bank acquired a new position in shares of Synthetic Biologics during the fourth quarter worth $356,000.

Synthetic Biologics Inc (NYSEMKT SYN) traded down 3.333% on Friday, reaching $0.522. 97,305 shares of the company’s stock traded hands. The firm’s market capitalization is $63.63 million. The stock has a 50-day moving average of $0.55 and a 200 day moving average of $0.64. Synthetic Biologics Inc has a 52 week low of $0.41 and a 52 week high of $1.90.

Synthetic Biologics (NYSEMKT:SYN) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. On average, equities analysts expect that Synthetic Biologics Inc will post ($0.18) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/11/bank-of-new-york-mellon-corp-raises-position-in-synthetic-biologics-inc-syn.html.

Several research analysts have commented on the stock. William Blair reiterated an “outperform” rating and set a $5.00 price target on shares of Synthetic Biologics in a report on Monday, May 22nd. Zacks Investment Research upgraded shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday. Finally, ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $4.51.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Want to see what other hedge funds are holding SYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synthetic Biologics Inc (NYSEMKT:SYN).

Institutional Ownership by Quarter for Synthetic Biologics (NYSEMKT:SYN)

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.